See more : EuropaCorp (ECP.PA) Income Statement Analysis – Financial Results
Complete financial analysis of COMPASS Pathways plc (CMPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of COMPASS Pathways plc, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Handok Clean Tech Co., Ltd. (256150.KQ) Income Statement Analysis – Financial Results
- Old National Bancorp (ONBPP) Income Statement Analysis – Financial Results
- China Public Procurement Limited (1094.HK) Income Statement Analysis – Financial Results
- DEFAMA Deutsche Fachmarkt AG (DEF.DE) Income Statement Analysis – Financial Results
- Alternative Income REIT PLC (AIRE.L) Income Statement Analysis – Financial Results
COMPASS Pathways plc (CMPS)
About COMPASS Pathways plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 0.00 |
| Gross Profit | -242.94K | -329.80K | -174.98K | -112.00K | -63.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 87.52M | 65.05M | 44.03M | 23.37M | 12.56M | 8.92M |
| General & Administrative | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| Other Expenses | 0.00 | -14.42M | -9.65M | -4.25M | -2.73M | -2.68M |
| Operating Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
| Cost & Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
| Interest Income | 0.00 | 0.00 | 40.00 | 319.00 | 73.00 | 0.00 |
| Interest Expense | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 22.00K |
| EBITDA | -123.80M | -110.40M | -83.22M | -47.04M | -18.39M | -10.52M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -136.92M | -110.40M | -83.22M | -51.39M | -21.18M | -12.50M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.24M | 19.31M | 11.68M | -8.91M | 1.58M | -716.00K |
| Income Before Tax | -117.68M | -91.10M | -71.54M | -60.30M | -19.60M | -13.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 780.00K | 408.00K | 199.00K | 32.00K | 15.00K | -716.00K |
| Net Income | -118.46M | -91.51M | -71.74M | -60.33M | -19.61M | -13.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
| EPS Diluted | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
| Weighted Avg Shares Out | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
| Weighted Avg Shares Out (Dil) | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
COMPASS Pathways plc (CMPS) Q2 2023 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Guy Goodwin - Chief Medical Officer Mike...
COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the second quarter 2023 and gave an update...
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2023, and...
This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock
COMP360 appears to be compatible with certain antidepressant medications. That's contrary to some prior assumptions, so it's a pleasant surprise.
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
COMP360 psilocybin treatment shows potential in exploratory open-label investigator-initiated study in anorexia nervosa COMP360 psilocybin treatment shows potential in exploratory open-label investigator-initiated study in anorexia nervosa
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
LONDON, July 17, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that positive data from an open-label phase 2 clinical trial of...
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
Alex Carchidi returns to update investors on the psychedelics industry. Collapse, consolidation, and why you shouldn't bet on just 1 stock.
COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down
COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down
Psychedelic Stocks: Don't Bet On Just 1 Company
Will tough times continue for psychedelic stocks? Analyst Alex Carchidi shares his views on the sector and specific stocks like Compass Pathways, Atai and Cybin.
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
LONDON, July 13, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper in the American Journal of Psychiatry...
Source: https://incomestatements.info
Category: Stock Reports